Crinetics Pharmaceuticals, Inc. (CRNX) Spending and interest coverage
- R&D / revenue · 12 months: Value 890.62%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 234.80%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 890.62% | Research and development expense / revenue. Period ending 2026-06-30. $375.45M ÷ $42.16M × 100 ≈ 890.62% |
| Stock-based compensation / revenue · 12 months | 234.80% | Share-based compensation / revenue. Period ending 2026-06-30. $98.98M ÷ $42.16M × 100 ≈ 234.80% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 375.45M USD | Research and Development Expense |
| Revenue | 42.16M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 98.98M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -549.09M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $375.45M | $42.16M | $98.98M | $-549.09M | (m) | 890.62% | 234.80% | (m) | (m) |
| 2026-03-31 | $355.90M | $18.07M | $100.23M | $-545.74M | (m) | 1969.67% | 554.68% | (m) | (m) |
| 2025-12-31 | $332.06M | $7.70M | $91.02M | $-516.77M | (m) | 4314.68% | 1182.74% | (m) | (m) |
| 2025-09-30 | $313.57M | $1.53M | $88.15M | $-477.85M | (m) | 20428.08% | 5742.61% | (m) | (m) |
| 2025-06-30 | $285.01M | $1.39M | $83.59M | $-423.06M | (m) | 20475.00% | 6005.32% | (m) | (m) |
| 2025-03-31 | $263.06M | $760.00K | $76.41M | $-376.73M | (m) | 34612.50% | 10053.95% | (m) | (m) |
| 2024-12-31 | $240.16M | $1.04M | $69.39M | $-338.85M | (m) | 23114.15% | 6678.15% | (m) | (m) |
| 2024-09-30 | $219.17M | (m) | $62.16M | $-306.77M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $201.10M | (m) | $55.06M | $-277.95M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $183.40M | (m) | $46.30M | $-248.16M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $168.53M | (m) | $40.94M | $-222.61M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $159.94M | $-15.00K | $37.27M | $-207.51M | (m) | -1066253.33% | -248453.33% | (m) | (m) |
| 2023-06-30 | $148.09M | $97.00K | $33.65M | $-191.98M | (m) | 152665.98% | 34693.81% | (m) | (m) |
| 2023-03-31 | $140.44M | $-452.00K | $30.61M | $-182.03M | (m) | -31071.02% | -6771.90% | (m) | (m) |
| 2022-12-31 | $130.22M | $0.00 | $28.27M | $-167.88M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $117.84M | $4.03M | $25.48M | $-151.21M | (m) | 2925.47% | 632.52% | (m) | (m) |
| 2022-06-30 | $107.43M | (m) | $22.60M | $-135.57M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $94.92M | $3.13M | $19.70M | $-118.61M | (m) | 3031.72% | 629.22% | (m) | (m) |
| 2021-12-31 | $84.25M | $0.00 | $17.35M | $-107.70M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $76.48M | (m) | $15.16M | $-98.61M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $68.60M | (m) | $13.39M | $-89.25M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $60.72M | (m) | $11.69M | $-80.09M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $57.00M | $71.00K | $10.43M | $-74.95M | (m) | 80278.87% | 14685.92% | (m) | (m) |
| 2020-09-30 | $52.31M | $392.00K | $9.29M | $-68.38M | (m) | 13344.64% | 2369.13% | (m) | (m) |
| 2020-06-30 | $50.44M | $897.00K | $8.36M | $-65.15M | (m) | 5622.63% | 932.00% | (m) | (m) |
| 2020-03-31 | $48.11M | $897.00K | $7.41M | $-61.57M | (m) | 5363.77% | 826.42% | (m) | (m) |
| 2019-12-31 | $41.51M | $1.19M | $6.29M | $-53.83M | (m) | 3479.13% | 527.58% | (m) | (m) |
| 2019-09-30 | $37.01M | $1.65M | $5.31M | $-48.05M | (m) | 2239.20% | 321.23% | (m) | (m) |
| 2019-06-30 | $32.08M | $1.70M | $4.23M | $-40.89M | (m) | 1891.33% | 249.47% | (m) | (m) |
| 2019-03-31 | $27.01M | $2.35M | $2.92M | $-33.23M | (m) | 1148.07% | 124.18% | (m) | (m) |
| 2018-12-31 | $24.48M | $2.43M | $2.32M | $-28.71M | (m) | 1008.20% | 95.55% | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $11.89M | $2.44M | (m) | (m) | (m) | 486.81% | (m) | (m) | (m) |
| 2017-12-31 | $9.23M | $2.04M | $271.00K | $-9.13M | $8.00K | 451.49% | 13.25% | -1140.88× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $5.10M | $589.00K | $270.00K | $-6.04M | $11.00K | 865.87% | 45.84% | -549.45× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.